International Speakers

Dr Susan Dent

University of Rochester Medical Center, USA

Dr Dent attended McMaster University Medical School in Hamilton, Ontario, Canada, and completed her residency training in Internal Medicine and Medical Oncology at the Ottawa Hospital, University of Ottawa, Ontario, Canada. She subsequently completed a post graduate research fellowship in clinical trials at the Canadian Cancer Trials Group (CCTG) in Kingston, Ontario, and was appointed as a staff medical oncologist in Thunder Bay, Ontario.

In 2001, Dr Dent returned to Ottawa, where she specialized in the treatment of breast cancer with a focus on new drug development. In 2008, Dr Dent established a multidisciplinary cardio-oncology clinic in Ottawa and in 2011, she founded the Canadian Cardiac Oncology Network (CONN), a not-for-profit organization devoted to optimization of cancer care for patients without compromising cardiovascular health. In 2015, Dr Dent launched the Global Cardio-Oncology Summit (GCOS), an annual meeting which now attracts oncologists, cardiologists, and allied health care providers from more than 23 countries.

Dr Dent is recognized for her efforts in the evaluation of novel cancer treatments for breast cancer while gaining a better understanding of the impact of these treatments on cardiovascular health. She is recognized as a global leader in cardio-oncology. She has travelled extensively around the world sharing her knowledge and expertise on cancer therapy related cardiovascular toxicity. She continues to work and build relationships with global organizations interested in cardio-oncology, including: European Society of Medical Oncology, American College of Cardiology, the American Heart Association, and the American Society of Clinical Oncology. Dr Dent currently serves as President of the International Cardio-Oncology society (ICOS), an organization dedicated to bringing cardiologists, oncologists, and allied health care providers together, to improve the clinical care of patients and save lives.

In September 2024, Dr. Dent accepted a staff position at the University of Rochester, New York, as a breast cancer medical oncologist, Director of Cardio-Oncology and Director of Survivorship at the Wilmot Cancer Institute.

Prof Dean Ho

National University of Singapore, Singapore

Professor Dean Ho is currently Provost's Chair Professor, Director of The Institute for Digital Medicine (WisDM) at the Yong Loo Lin School of Medicine; Director of The N.1 Institute for Health (N.1), and Head of the Department of Biomedical Engineering at the National University of Singapore (NUS).

Prof. Ho and collaborators manage a portfolio of over 10 prospective, interventional human clinical trials. His team successfully developed and validated CURATE.AI, a powerful artificial intelligence platform that personalizes human treatment for a broad spectrum of indications ranging from oncology, to digital therapeutics and infectious diseases, among others. His team also developed IDentif.AI to optimise combination therapy design against SARS-CoV-2 and to address antimicrobial resistance.

Prof. Ho is an elected Fellow of the US National Academy of Inventors (NAI), American Association for the Advancement of Science (AAAS), the American Institute for Medical and Biological Engineering (AIMBE), and the Royal Society of Chemistry. He was also named to the HIMSS Future50 Class of 2021 for his internationally recognised leadership in digital health. Prof. Ho is also a Subgroup Lead in the World Health Organization (WHO) Working Group for the regulation of AI for Health, which was recently released globally.

Prof. Ho is an author of the best-selling book, Medicine Without Meds, which has released internationally. The book serves as a blueprint for a broad community—from business leaders and venture capitalists to healthcare systems—on how to accelerate practice-changing innovation to patients and caregivers. All author proceeds from the book will be benefiting the WisDM Patient Impact Fund at NUS.

In popular and international media, Prof. Ho has appeared on the National Geographic Channel Program “Known Universe,” and Channel News Asia's “The Hidden Layer: Healthcare Trailblazers.” His discoveries have been featured on CNN, The Economist, Straits Times, National Geographic, Forbes, Washington Post, NPR, and other international news outlets.

Prof. Ho is a recipient of the Tech Heroes from Crisis Pathfinder Award from the Singapore Computer Society, NSF CAREER Award, Wallace H. Coulter Foundation Translational Research Award, and V Foundation for Cancer Research Scholar Award, among others. He has also served as the President of the Board of Directors of the Society for Laboratory Automation and Screening (SLAS), a leading global drug development organization.

A/Prof Danielle Rodin

Princess Margaret Cancer Centre, Canada

Danielle Rodin, MD, MPH, FRCPC, is a radiation oncologist at Princess Margaret Cancer Centre and an Assistant Professor in the Department of Radiation Oncology at the University of Toronto (UTDRO), with a clinical practice focused on breast cancer and haematologic malignancies.

She is Director of the PM Global Cancer Program, Director of Equity, Diversity, and Professionalism at UTDRO, and an elected member of the Board of Directors for the Union for International Cancer Control (UICC) in Geneva.

Dr Rodin's research focuses on the affordability of cancer treatment, reducing disparities in access to cancer services, and improving the quality of life and outcomes of individuals with cancer, both locally and globally.

Dr Rodin received her B.A. (Hons.) from McGill University, her MD from the University of Toronto, and her Master of Public Health from Harvard University.

She was the 2017–2018 Harkness Fellow in Health Care Policy and Practice in the Department of Health Policy and Management at the Harvard T. H. Chan School of Public Health, where she focused on value-based care across international health systems.

Dr Robin Zon

ASCO President-Elect, USA

Dr Zon currently serves as the Director of Breast Cancer Oncology at the Cincinnati Cancer Advisors (CCA), a provider of no-cost second opinions to recently diagnosed cancer patients in or near the Greater Cincinnati area.

Prior to joining CCA, Dr Zon served as Past President, and is now Physician Emeritus at Michiana Hematology Oncology in Mishawaka, IN.

She formerly served as Medical Director of Oncology Research at Memorial Hospital and NCI CCOP Associate and then Principal Investigator until 2013 for the Northern Indiana Cancer Research Consortium, the only NCI designated Community Cancer Oncology Program in the state of Indiana.

Dr Zon is an active volunteer for ASCO, most recently being awarded ASCO's Advocate of the Year for her significant advocacy work on behalf of individuals living with cancer and their cancer care teams and was the recipient of ASCO's Distinguished Achievement Award.

Dr Zon is a Past Chair of ASCO's Government Relations Committee, where she provided distinguished leadership in the society's advocacy efforts. She also served on the Board of Directors from 2010 to 2013, along with participating in many other ASCO-related responsibilities.